Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine.

The low-molecular-weight imidazoquinolinamine derivative, 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine (imiquimod, previously described as R-837), induced alpha-interferon (IFN-alpha) in mice. IFN induction was identified at oral doses as low as 3 mg/kg. The 10% lethal dose for daily treatment with imiquimod was 200 mg/kg. Oral treatment with 30 mg/kg imiquimod once every three days significantly inhibited MC-26 colon carcinoma. Delay of treatment from day 1 to day 5, when tumors were easily palpable, did not reduce benefits. Ten daily treatments were slightly more effective than five. However, delivery of the same total dose of imiquimod either once every day for 20 days, once every 4 days, once every 7 days, or once every 10 days inhibited tumor growth to the same level. The antitumor effects of imiquimod were significantly abrogated by an antiserum to murine IFN-alpha, suggesting that the antitumor effect was to a substantial extent mediated by IFN induction. Imiquimod also significantly reduced the number of lung colonies in mice inoculated i.v. with MC-26 tumor cells. Combination of treatment with imiquimod and cyclophosphamide was significantly (P less than 0.01) better than treatment with either drug alone. Combination treatment with cyclophosphamide led to cures in some of the mice inoculated either s.c. or i.v. with MC-26 cells. Treatment with imiquimod also inhibited the growth of RIF-1 sarcoma and Lewis lung carcinoma but was ineffective for P388 leukemia. Imiquimod is an oral IFN-alpha inducer with antitumor effectiveness for transplantable murine tumors.

[1]  M. Hilleman,et al.  Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. , 1967, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Kendall A. Smith,et al.  T cell growth factor: parameters of production and a quantitative microassay for activity. , 1978, Journal of immunology.

[3]  S. Grossberg,et al.  Virus yield-reduction assays for interferon: picornavirus hemagglutination measurements. , 1981, Methods in enzymology.

[4]  M. Droller,et al.  Inhibition of tumor growth in association with modification of in vivo immune response by indomethacin and polyinosinic:polycytidylic acid. , 1982, Cancer research.

[5]  D. Stringfellow.  Nonpolynucleotide Inducers of Interferon , 1984 .

[6]  D. A. Flick,et al.  Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. , 1984, Journal of immunological methods.

[7]  E. Borden,et al.  An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma. , 1985, Journal of biological response modifiers.

[8]  E. Borden,et al.  Inhibitory effects of interferon-inducing pyrimidinones on the growth of transplantable mouse bladder tumors. , 1986, Cancer research.

[9]  M. Kende,et al.  Treatment of Experimental Viral Infections with Immunomodulators , 1988 .

[10]  D. Bernstein,et al.  Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. , 1988, Antiviral research.

[11]  M. Chen,et al.  Efficacy of S26308 against guinea pig cytomegalovirus infection , 1988, Antimicrobial Agents and Chemotherapy.

[12]  E. Borden,et al.  Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta. , 1988, Cancer research.

[13]  D. Bernstein,et al.  Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections , 1989, Antimicrobial Agents and Chemotherapy.